Telomir Pharmaceuticals (NASDAQ: TELO) has announced the publication of peer-reviewed preclinical data in Advances in Redox Research showing that its lead compound, Telomir-Zn, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The findings, detailed in a press release, indicate that Telomir-Zn reduced oxidative stress, lowered hepatic copper burden, and improved liver function markers, supporting its biological activity in this rare genetic disorder.
Wilson’s disease is a genetic condition characterized by copper accumulation in the body, primarily affecting the liver and brain. Current treatments include chelation therapy and zinc acetate, but many patients experience side effects or inadequate disease control. The preclinical results suggest Telomir-Zn may offer a novel approach by modulating intracellular metal homeostasis and redox balance, mechanisms linked to its broader activity in cancer and aging.
The study expands the scientific validation for Telomir-Zn as the company advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation. Telomir Pharmaceuticals, a preclinical-stage biotechnology company, focuses on small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company’s press release noted that Telomir-Zn has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The publication in a peer-reviewed journal adds credibility to the findings, which could have implications for Wilson’s disease patients and the broader field of metal-related disorders. For investors, the data strengthens the case for Telomir’s platform technology, potentially opening up additional indications beyond oncology. The company’s newsroom provides the latest updates on TELO, and the full press release is available for review.
This news matters because Wilson’s disease affects approximately 1 in 30,000 individuals worldwide, and there is a need for improved therapies. If Telomir-Zn advances to clinical trials, it could offer a new treatment option for patients who do not respond well to existing therapies. Additionally, the compound’s mechanism of action may have relevance to other conditions involving metal dyshomeostasis, such as neurodegenerative diseases.
The preclinical data represent a step forward for Telomir Pharmaceuticals as it builds its pipeline. However, the company remains in preclinical stages, and further research and clinical trials will be necessary to determine the compound’s safety and efficacy in humans.
